Unruptured intracranial aneurysm as a cause of cerebral ischemia

Department of Neurology, Toulouse University, Toulouse, France.
Clinical neurology and neurosurgery (Impact Factor: 1.13). 10/2010; 113(1):28-33. DOI: 10.1016/j.clineuro.2010.08.016
Source: PubMed

ABSTRACT Unruptured intracranial artery aneurysms (IAs) can be revealed by cerebral ischemia. Little is known on the clinical course and outcome of patients with this condition. We report our findings in a consecutive series of 15 such patients.
We retrospectively analyzed patients with ischemic stroke (IS) or transient ischemic attack (TIA), unruptured IA on the symptomatic cerebral artery, and no other potential cause of cerebral ischemia consecutively treated in a tertiary stroke unit.
Fifteen patients (ten women, and five men) were identified. Their mean age was 49.7 years (range, 37-80 years). Ten patients presented with IS, and five with TIA. The median diameter of IA was 7.5mm (range, 2.5-23 mm). Aneurysm thrombosis was found on imaging in 9/10 patient with IS, and 1/5 patients with TIA (p=0.017). Thirteen patients were given an antiplatelet agent. Mean follow-up until last visit or treatment of aneurysm was 393 days (median 182 days; range, 6-1825 days). There was no ischemic recurrence. Partial or complete recanalization of aneurysm thrombosis occurred in 7/10 patients. Two patients, both with initial aneurysmal thrombosis and on antiplatelet therapy, experienced aneurysm rupture.
Unruptured IA is a rare cause of IS/TIA. IS is associated with aneurysm thrombosis. Our findings suggest that aneurysm thrombosis is a dynamic process which is associated with a low rate of ischemic recurrence on antiplatelet therapy but may be followed by subarachnoid hemorrhage.

5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present study aimed to investigate the endovascular indication with close monitoring of both endovascularly treated and untreated unruptured vertebrobasilar aneurysms. In the past 2 years, 36 patients [7 women and 29 men with a mean age of 48.5 years (range, 13-75 years)] who had 40 unruptured vertebrobasilar artery aneurysms were reviewed. The decision of the endovascular treatment was not randomized. In both endovascularly untreated and treated patients, overall mortality and morbidity corresponding to Glasgow outcome scale (GOS) score III or worse was counted as unruptured aneurysm related event. The ratio of event free was compared between endovascularly treated and untreated patients using Log-rank test. In a univariate analysis, poor outcome was predicted by endovascularly untreated. Thirty-six patients were followed with a mean period of 10.7 months (range, 0.7 months-21 months). In untreated cases, new neurological deficits caused by the aneurysm were noted in 2 cases. The annual deterioration rate of the untreated cases was 9.1%. In endovascularly treated cases, there was no mortality and morbidity. There was no SAH in all cases during follow-up period. When ratio of event free was compared, significant advantage of endovascular treatment was noted (X(2)=4.429, P=0.035). The present results indicated that endovascular treatment has a benefit for the unruptured vertebrobasilar artery aneurysms.
    European journal of radiology 12/2011; 81(10):2741-5. DOI:10.1016/j.ejrad.2011.11.046 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stroke remains a major cause of death in the US and around the world. Despite major scientific advances in our understanding of stroke pathology, the only FDA-approved drug for ischemic stroke is tissue plasminogen activator (tPA). Moreover, the therapeutic window for tPA is confined to the acute phase of stroke, thereby greatly limiting its benefits to less than 3% of ischemic stroke patients. Many treatment strategies for stroke have targeted the subacute or chronic phase in an effort to abrogate the secondary cell death that ensues after the initial stroke insult. Here, we advance the hypothesis that blood vessel disruption, or aneurysm, in the brain is an exacerbating factor for stroke, especially in the evolution of the penumbra or peri-infarct area. A better understanding of aneurysm, specifically its dynamic onset and juxtaposition to the ischemic brain tissue should facilitate the development of novel strategies for attenuating the secondary cell death associated with stroke. To this end, we discuss the laboratory and clinical evidence implicating aneurysm formation in stroke and also provide insights on how stem cell therapy may prove efficacious in combating aneurysm and stroke.
    Current pharmaceutical design 05/2012; 18(25):3663-9. DOI:10.2174/138161212802002724 · 3.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Management of ischemic stroke in the presence of aneurysmal brain disease is controversial. Recent retrospective evidence suggests that in selected patients, intravenous thrombolysis (IVT) remains a safe approach for reperfusion. We document a case of post-thrombolysis aneurysmal rupture. Supported by additional scientific literature we postulate that acute aneurysmal thrombosis leading to stroke in the culprit artery may be an ominous sign of rupture and should be considered separately from fortuitously discovered distant aneurysmal disease. A 71-year-old female presented with an acute right middle cerebral artery stroke syndrome. IVT allowed vessel reperfusion and revealed a previously concealed, juxtaposed non-giant M1 segment saccular aneurysm. Secondary aneurysmal rupture ensued. The aneurysm was secured by surgical clipping. Postoperative course was uneventful. This case shows that despite reports of thrombolysis safety in the presence of brain aneurysms, thrombolysis remains potentially hazardous and hints toward an increased risk when the stroke arises on the parent vessel itself. Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.
    Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association 12/2014; 24(3). DOI:10.1016/j.jstrokecerebrovasdis.2014.10.004 · 1.67 Impact Factor